Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Victrix CMCC Chooses Cresset’s Software for Drug Discovery Consulting Projects

Published: Friday, June 28, 2013
Last Updated: Friday, June 28, 2013
Bookmark and Share
Cresset’s software will help Victrix clients to carry out structure based drug design projects.

Under a new agreement, Victrix CMCC will use Cresset’s software for their computational chemistry consulting projects.

Cresset’s Spark, Forge and Torch software will help Victrix clients to carry out structure based drug design projects and build predictive 3D SAR models for lead identification.

“Victrix is very pleased to be able to offer our clients access to Cresset's software,” says Dr Adam Kallel, CSO of Victrix. “Cresset’s field based software significantly expands our ability to help clients with programmes that have little or no structural information.”

Dr Kallel adds, “I have been a believer in field based methodology since I began work in the pharmaceutical industry and I was an early adopter of the Cresset technology. I believe the XED force field that underlies Cresset’s software provides the ability to model molecules and their molecular fields in a way that is as close to high level quantum mechanics as possible, giving valuable insights into structure reactivity relationships. I strongly recommend its use and am very pleased to provide this functionality to Victrix clients."

“We are delighted that Victrix has chosen to use Cresset’s software for their consulting projects,” says Dr Robert Scoffin, CEO of Cresset. “Our field based approach of using 3D shape and electrostatics to understand molecular function is particularly valuable when there is no information available about the protein target. We look forward to Victrix clients experiencing the difference our software will make to their research.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cresset Donates to Novartis’ TExts to Sub-Saharan Africa Project
Project donates textbooks to Kenyan university libraries.
Tuesday, September 30, 2014
CloudScientific Appointed as Cresset’s Distributor in China
CloudScientific appointed as distributor of computational chemistry software.
Friday, July 11, 2014
Locating and Explaining ‘Activity Cliffs’ in SAR Datasets
Activity Miner from Cresset is an intuitive SAR interpretation tool, identifying key 3D structural and electrostatic changes that impact molecular activity.
Monday, September 16, 2013
Cresset Announces new International Sales Team
Cresset has expanded its computational chemistry software sales team in the U.S. and Europe.
Thursday, September 09, 2010
Cresset Announces Appointment of Rob Scoffin as new CEO
Rob replaces Beatrice Leigh, who will now become non-executive Chairman of the Board.
Monday, April 26, 2010
Cresset Expands Sales Pipeline Potential through CambridgeSoft Alliance
CambridgeSoft sells Cresset’s FieldAlign and FieldTemplater products using its direct, telesales and ecommerce channels.
Monday, April 20, 2009
Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
New Hope for Personalized Treatment of Eczema
Pharmaceutical researchers at Oregon State University have developed a new approach to treat eczema and other inflammatory skin disorders that would use individual tests and advanced science to create personalized treatments based on each person's lipid deficiencies.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Combination Drug Therapy Shrinks Pancreatic Tumors In Mice
Two drugs that affect the structure and function of DNA have been found to block the growth of pancreatic tumor cells in mice, researchers hope the drugs can soon be tested in humans with the disease.
Seeking A Better Way To Design Drugs
NIH funds research at Worcester Polytechnic Institute to advance a new chemical process for more effective drug development and manufacturing.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Diabetes Drugs May Actually Release Sugar Into the Blood
A family of drugs used to treat Type 2 diabetes could promote the release of sugars into the blood - something the drugs are supposed to prevent, Cambridge scientists have claimed.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos